Immuneering reports Q1 2025 results: net loss $15M, positive IMM-1-104 data, CMO named

Immuneering Corp

2025-Q1 EPS reported -$0.42

Net loss $15.0M ($0.42/sh) vs $14.3M ($0.49/sh) in Q1 2024; R&D expenses $11.5M.
Cash $35.9M as of March 31, 2025; runway extended into 2026.
Positive IMM-1-104 data: 13-month monotherapy PFS in third-line pancreatic cancer; complete response in first-line combo with chemo.
Named Dr. Igor Matushansky as CMO; signed clinical supply agreement with Regeneron for Libtayo combo in NSCLC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.